23 August 2026
: Case report
[In Press] Case Report: Botulinum Toxin Type A Injection for Bruxism Following Left Basal Ganglia Hemorrhage
Unusual or unexpected effect of treatment
Jialing Wang1ABEF, Xudong Zhu2CFG, Yanjie Fu1ACD, Ya Zheng1ACDDOI: 10.12659/AJCR.953163
Am J Case Rep In Press; DOI: 10.12659/AJCR.953163
Available online: 2026-08-23, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Post‑stroke bruxism is an underrecognized complication that may impair oral function, cause orofacial pain, and negatively impact rehabilitation outcomes. Botulinum toxin type A (BoNT‑A) has been reported for bruxism, but its application in post‑stroke populations remains sparsely documented. This case describes the assessment and treatment of bruxism following cerebral hemorrhage, utilizing the Standardized Tool for the Assessment of Bruxism (STAB) as a structured multidimensional framework.
CASE REPORT
A 40-year-old man developed bruxism during recovery from a massive left hemispheric intracerebral hemorrhage after decompressive craniectomy and hematoma evacuation. About 3 months after admission, he began to exhibit bilateral masseter muscle hypertrophy with marked tenderness, temporomandibular joint pain, and drooling from the right mouth corner, with no prior history of bruxism. STAB-based evaluation yielded the following Axis A findings: Subject-based assessment revealed nocturnal grinding reported by caregivers. Clinically based assessment revealed bilateral masseter hypertrophy, tenderness on palpation, and dental wear. Instrument-based assessment (surface electromyography used for injection guidance) confirmed increased masseter muscle activity at rest and during clenching. Symptoms were refractory to occlusal splint therapy combined with hot compresses. At 48 hours after electromyography-guided injection into the bilateral masseter muscles (50 U per side, divided into 3 sites per side), muscle tension and tenderness were markedly reduced, and clinical improvement persisted at 6-month follow-up.
CONCLUSIONS
In this single case, BoNT‑A injection was temporally associated with symptom relief in post-stroke bruxism. STAB provided a structured multidimensional assessment framework. These descriptive findings have limited generalizability. Controlled studies are needed to establish the efficacy and safety of this intervention in the post‑stroke population.
Keywords: Botulinum Toxins, Type A; Bruxism; Cerebral Hemorrhage
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953929
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953439
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953653
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952921
Most Viewed Current Articles
07 Dec 2021 : Case report
22,772,684
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
178,948
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
122,859
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
67,338
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






